Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

August 31, 2015 11:23 AM ET


Company Overview of Mersana Therapeutics, Inc.

Company Overview

Mersana Therapeutics, Inc. engineers antibody-drug conjugates that maximize the potential of new and established therapeutic classes. The company develops a portfolio of antibody-drug conjugates to improve patient outcomes in multiple oncology indications. Its clinical-stage product candidates include XMT-1001, a “tecan” conjugate for patients with lung cancers; and XMT-1107, an anti-angiogenic conjugate for patients with refractory, advanced solid tumors. The company’s conjugation system provides benefits for the development of drugs across therapeutic modalities, including antibody-drug conjugates, antibody fragments, small molecules, biologics, and synergistic drug combinations. Mersana T...

840 Memorial Drive

Cambridge, MA 02139

United States

Founded in 2001





Key Executives for Mersana Therapeutics, Inc.

Chief Executive Officer, President and Director
Age: 51
Executive Chairman
Age: 50
Vice President of Finance
Head of Clinical Development & Regulatory Affairs
Age: 60
Compensation as of Fiscal Year 2015.

Mersana Therapeutics, Inc. Key Developments

Mersana Therapeutics, Inc. Presents at Wedbush PacGrow Healthcare Conference 2015, Aug-12-2015 03:40 PM

Mersana Therapeutics, Inc. Presents at Wedbush PacGrow Healthcare Conference 2015, Aug-12-2015 03:40 PM. Venue: Le Parker Meridian, 119 West 56th Street, New York, NY 10019, United States.

Mersana Therapeutics, Inc. Presents at Sachs Immuno-Oncology: BD&L and Investment Forum, May-29-2015

Mersana Therapeutics, Inc. Presents at Sachs Immuno-Oncology: BD&L and Investment Forum, May-29-2015. Venue: Hyatt Chicago Magnificent Mile, Chicago, Illinois, United States. Presentation Date & Speakers: May-29-2015, Eva M. Jack, Chief Business Officer.

Mersana Therapeutics, Inc. Announces Preclinical Data for its Lead Product Candidate, XMT-1522

Mersana Therapeutics, Inc. announced that preclinical data for its lead product candidate, XMT-1522, demonstrated significant anti-cancer activity in low HER2-expressing tumor models refractory to currently available therapies, as well as HER2-amplified tumor models in combination with trastuzumab-based therapies. These data will be presented at the American Association for Cancer Research (AACR) Annual Meeting on April 21 in Philadelphia, PA. XMT-1522 is a novel HER2-targeting therapy based on Mersana's Fleximer® immunoconjugate technology that carries an average of 15 proprietary auristatin payload molecules. The conjugate, optimized for payload delivery, utilizes a novel HER2-targeted antibody, which binds to a different epitope than existing anti-HER2 antibodies. Single doses of 1 mg/kg or 0.67 mg/kg of XMT-1522 showed complete regression in low HER2-expressing breast and gastric cancer models, where ado-trastuzumab emtansine was inactive at doses of 10 mg/kg and above. In HER2-driven tumor models, XMT-1522 showed synergistic efficacy in combination with widely used anti-HER2 therapies trastuzumab and pertuzumab. XMT-1522 demonstrated an excellent pharmacokinetic profile and was well tolerated in non-human primates at therapeutic doses.

Similar Private Companies By Industry

Company Name Region
Cadista Holdings Inc. United States
AccelaPure Corporation United States
Phrixus Pharmaceuticals, Inc. United States
DesignMedix, Inc United States
Scherer R P International Corp United States

Recent Private Companies Transactions

Private Placement
February 20, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Mersana Therapeutics, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at